Enzo Health closes $20M Series A

Home health software is having a moment — and Enzo Health just gave a pretty clear signal why. On May 4, the Lehi, Utah startup said it closed a $20 million Series A led by N47, bringing total funding to $26 million. The pitch is not flashy. It is basically this: home health agencies are drowning in intake work, documentation, coding, and compliance, while more care keeps shifting out of hospitals and into living rooms. Enzo wants to be the AI layer that makes that mess manageable. (enzo.health) ### What does Enzo actually sell? Enzo sells workflow software for home health and post-acute care teams. Its products handle referral intake, visit documentation, coding, QA, and compliance-heavy chart review — the back-office and clinician admin work that slows agencies down and burns staff out. On its own site, Enzo says its scribe too(enzo.health)t helps agencies make admit decisions faster. (enzo.health) ### Why is that a real problem now? Because demand is rising faster than the workforce. Enzo’s announcement leans on two blunt numbers: more than 10,000 Americans turn 65 each day, and 7 in 10 will need long-term care at some point. That does not just mean more patients. It means more referrals to review, more home visits to document, more reimbursement rules to navi(enzo.health)already run on thin staffing. (enzo.health) ### Who backed this round? N47 led the Series A, with existing investors Gradient, Tandem Ventures, and Rigby Watts participating. One small wrinkle matters here — some coverage calls the lead investor “N47,” while other writeups identify the firm as Next47. Either way, the investor set is telling. These are backers that like workflow-hea(enzo.health)pitch as infrastructure for care delivery. (homehealthcarenews.com) ### Where does the money go? Mostly into expansion. Enzo says the fresh capital will help it deepen its home health products and push into skilled nursing and hospice. That matters because those settings share the same ugly traits — fragmented workflows, heavy regulation, and lots of human coor(homehealthcarenews.com)eatures. It is trying to widen the category it can serve. (homehealthcarenews.com) ### Is this just another AI scribe story? Not really — or at least not only that. The company is framing itself less as a note-taking tool and more as an operating layer across the full post-acute workflow, from referral to reimbursement. That is a bigger claim, and a harder one to pull off. A (homehealthcarenews.com)ange margins. That is the part investors are really buying. (enzo.health) ### What is the catch? Healthcare AI in regulated settings always runs into the same wall — accuracy is not enough. The software has to fit billing rules, audit trails, clinical nuance, and messy real-world agency workflows. Enzo’s own marketing leans heavily on compliance and human review, which is a clue that the company knows full automation is not the near-term s(enzo.health)wer clicks, faster charts, cleaner submissions. (enzo.health) ### Why does this round matter beyond Enzo? Because it shows where health tech money is looking now. Not at moonshot care delivery models, but at boring, painful operational bottlenecks in sectors with rising demand. Axios reported Enzo is already thinking about a Series B next year in the $30 million to $40 million range. So this round looks less like a finish line (enzo.health)ome essential plumbing for post-acute care before the demographic wave gets even bigger? (axios.com) ### Bottom line? Enzo’s raise is a bet that the next healthcare software winner may come from the least glamorous corner of the system — home health paperwork. If the company can turn AI from a demo into dependable workflow infrastructure, the opportunity is big. If not, it becomes one more startup that learned healthcare admin is harder than it looks.